Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700207 | 0.81 | KMT2A (0.55) | NR4A1RAB9ACYP11B2SMN1; SMN2ALDH1A1 | |
| SCHEMBL3671003 | 0.80 | RAB9A (0.60) | RAB9AHTTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3232949 | 0.78 | SRD5A2 (0.90) | SRD5A2NR4A2NR4A1NR4A3PTGES | |
| SCHEMBL8503299 | 0.77 | SRD5A2 (0.77) | SRD5A2NR4A2NR4A1NR4A3PTGES | |
| SCHEMBL402300 | 0.76 | SRD5A2 (0.87) | SRD5A2NR4A2NR4A1NR4A3PTGES | |
| SCHEMBL25306107 | 0.76 | POLB (0.59) | RAB9AALDH1A1L3MBTL1KMT2A | |
| SCHEMBL15064836 | 0.75 | SRD5A2 (0.61) | SRD5A2NR4A2NR4A1NR4A3PTGES | |
| SCHEMBL1921967 | 0.75 | ROCK2 (0.50) | SRD5A2NR4A1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL22492820 | 0.74 | ROCK2 (0.57) | RAB9ASMN1; SMN2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL4000884 | 0.74 | PTGES (0.71) | SRD5A2NR4A2NR4A1NR4A3PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3405192-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2024-12-11 | — | — | EP | disclosed |
| CN-109310671-B | Bruton's tyrosine kinase inhibitors | 淄博百极常生制药有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10793566-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-10793566-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190276453-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190276453-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-09-12 | — | — | US | disclosed |
| EP-3405192-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. (CN) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127371-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNNYLIFE PHARMA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662187-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | SRD5A2 3110/4885NR4A2 4151/4885NR4A1 3906/4885 |
| US-10793566-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | SRD5A2 3110/4885NR4A2 4151/4885NR4A1 3906/4885 |
| US-20190276453-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SRD5A2 3110/4885NR4A2 4151/4885NR4A1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.